RTTNews汇总多只小盘生物科技和医疗器械股盘中异动，未形成单一可交易强催化

Several biotech and medical device stocks were in focus Friday, including Pro-Dex following strong fiscal 2026 results; Modular Medical after FDA clearance for Pivot patch pump software enhancements; and ENvue Medical following its selection for the Vizient Innovative Technology Exchange. Attovia Therapeutics and Pyxis Oncology also gained after providing clinical and investor updates.
Read on…PRO-DEX INC. (PDEX) reported strong fiscal 2026 fourth-quarter and full-year results, with shares rising more than 16% Friday.
Fourth-quarter net sales increased 17% to $20.41 million from $17.49 million a year earlier, while net income rose to $2.86 million, or $0.87 per share, from $1.20 million, or $0.36 per share.
For fiscal 2026, net sales grew 16% to $77.55 million from $66.59 million, while net income increased to $13.66 million, or $4.12 per share, from $8.98 million, or $2.67 per share.
Currently, PDEX is trading at $72.05, up 16.59%.
Modular Medical Inc. (MODD) announced FDA clearance for software enhancements to its Pivot tubeless insulin patch pump.
The upgrades expand bolus dosing flexibility, allowing users to adjust the amount of insulin delivered with each button press, while also adding an updated user interface and other software improvements.
Modular plans to begin the first phase of Pivot's commercial rollout in October 2026 across Atlanta, Cincinnati/Lexington, Dallas, Houston and Philadelphia.
Currently, MODD is trading at $3.64, up 6.12%.
ENvue Medical Inc. (FEED) announced that it was selected to exhibit its ENvue Navigation Platform at the Vizient Innovative Technology Exchange on September 24, 2026, in Las Vegas.
The platform uses electromagnetic navigation to guide feeding tube placement and confirm positioning at the bedside in real time, eliminating the need to wait for X-ray confirmation.
An independent study of 531 procedures found zero inadvertent lung placements and a 67% reduction in ventilator-associated pneumonia, with ENvue estimating more than $1.5 million in first-year hospital cost savings.
Currently, FEED is trading at $4.02, up 5.09%.
Attovia Therapeutics Inc. (ATTO) reported a second-quarter 2026 net loss of $20.69 million, or $4.88 per share, compared with $14.44 million, or $3.71 per share a year earlier. R&D expenses rose to $18.9 million from $13.6 million, while cash, cash equivalents and marketable securities totaled $115.13 million.
The company plans a global Phase 2 trial of ATTO-1310 in the first half of 2027 following positive preliminary Phase 1b results. Attovia will also participate in Citi's 2026 Biopharma Back to School Conference on September 10 and the Morgan Stanley Global Healthcare Conference on September 16.
Currently, ATTO is trading at $26.93, up 11.28%.
Pyxis Oncology, Inc. (PYXS) reported second-quarter 2026 net loss of $25.3 million, or $0.40 per share, compared with $18.4 million, or $0.30 per share a year earlier. R&D expenses were $16.1 million, while cash, cash equivalents and short-term investments totaled $34.5 million as of June 30.
The company expects updated Phase 1 MICVO monotherapy data in recurrent/metastatic head and neck cancer in fall 2026 and Phase 1/2 combination data with KEYTRUDA in the fourth quarter.
Pyxis will also participate in three investor conferences in September, including the Wells Fargo Healthcare Conference on September 10, the Cantor Global Healthcare Conference on September 11 and the H.C. Wainwright Global Investment Conference on September 14.
Currently, PYXS is trading at $3.91, up 9.68%.
Did you know?
Scientists can now create miniature models of the brain, heart, liver, kidney, lung and intestine from stem cells. These organoids can mimic important features of human tissues and are increasingly being explored for disease research, drug screening and personalized medicine.
For comments and feedback contact: editorial@rttnews.com
Business News
August 28, 2026 14:11 ET Consumer prices data and economic output figures were the main news on the economics front in the U.S. this week. Similarly, latest data on demand for durable goods also drew attention. Survey data on the business morale in the biggest euro economy, Germany, were in focus in Europe. In Asia, the interest rate announcement from South Korea was the highlight.